THRV-1268 is under clinical development by Thryv Therapeutics and currently in Phase I for Atrial Fibrillation. According to GlobalData, Phase I drugs for Atrial Fibrillation have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how THRV-1268’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
THRV-1268 overview
LQT-1268 is under development for the treatment of atrial fibrillation and heart failure with preserved ejection fraction (HFpEF). It acts by targeting serine/threonine-protein kinase (SGK1). It is administered through oral route.
Thryv Therapeutics overview
Thryv Therapeutics is a biopharmaceutical company designed to develop novel therapeutics to treat QT syndrome, arrhythmias, atrial fibrillation and treatment resistant cancer diseases. The company is headquartered in Montreal, Quebec, Canada.
For a complete picture of THRV-1268’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
